Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | TGM1 | P22735 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30994771 | 0.94 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14428303 | 0.94 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29333221 | 0.94 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29080042 | 0.89 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL100555 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3444915 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL541346 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14068102 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL21681858 | 0.88 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1190328 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12570666-B2 | Furoindazole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-10 | — | — | US | disclosed |
| EP-4631940-A1 | COMPOUND TARGETING PAN-KRAS PROTEIN DEGRADATION AGENT AND USE THEREOF | Betta Pharmaceuticals Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| WO-2025089370-A1 | COMPOUNDS AS CSF1R INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-01 | — | — | WO | disclosed |
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | SMN1; SMN2 2424/4885NPC1 614/4885RAB9A 2797/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | SMN1; SMN2 1447/4885NPC1 591/4885RAB9A 2919/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | SMN1; SMN2 2424/4885NPC1 614/4885RAB9A 2797/4885 |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | SMARCA2, SMARCE1, SMARCA1 | SMN1; SMN2 332/4885NPC1 3404/4885RAB9A 3492/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | SMN1; SMN2 2424/4885NPC1 614/4885RAB9A 2797/4885 |
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | SMN1; SMN2 2861/4885NPC1 4305/4885RAB9A 1437/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | SMN1; SMN2 1788/4885NPC1 782/4885RAB9A 2278/4885 |
| US-12570666-B2 | Furoindazole derivatives | FURIN, CYP2F1, CYP3A7 | SMN1; SMN2 3218/4885NPC1 162/4885RAB9A 204/4885 |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | SMN1; SMN2 1964/4885NPC1 3795/4885RAB9A 269/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4618/4885NPC1 1359/4885RAB9A 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.